James E. Levine is CFO at Cardiff Oncology, Inc. (CRDF). They have made 9 open-market trades across 3 companies since 2010, most recently 2024-12-18.
CIK 0001463151
9 open-market purchases totalling $801K since 2010, never a sale. Across 5 scored buys the stock is up 1.6% at ninety days, and 6.4 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 40% | 20% | 40% |
| Avg Move | -3.7% | -9.3% | +1.6% |
| Alpha | -4.1% | -12.4% | -6.4% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CRDF | BUY | 2024-12-16 | 2024-12-18 | $4.76 | $37K | -12.0% | -30.0% | -23.1% |
| CRDF | BUY | 2022-09-16 | 2022-09-19 | $1.56 | $47K | -11.0% | -13.3% | -27.7% |
| CRDF | BUY | 2021-09-10 | 2021-09-13 | $6.47 | $194K | +7.2% | -5.3% | -16.5% |
| CDTX | BUY | 2020-11-10 | 2020-11-12 | $2.01 | $201K | -7.6% | -18.0% | +3.2% |
| CDTX | BUY | 2019-09-24 | 2020-03-23 | $1.91 | $57K | +4.8% | +20.2% | +72.4% |
| VRNM | BUY | 2012-05-15 | 2012-05-16 | $3.65 | $18K | N/A | N/A | N/A |
| VRNM | BUY | 2011-08-25 | 2011-08-29 | $3.18 | $80K | N/A | N/A | N/A |
| VRNM | BUY | 2011-08-12 | 2011-08-16 | $1.69 | $42K | N/A | N/A | N/A |
| VRNM | BUY | 2010-08-13 | 2010-08-17 | $2.51 | $125K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.